Summary: Open label Randomized clinical trial for noninferiority in seropositive Kidney transplant recipients receiving induction with ATG.

Objectives:

At the conclusion of this activity, the learner should be able to:

• Identify current Prophylaxis for CMV seropositive Kidney Recipients
• Recognize when it is effective and safe to discontinue CMV prophylaxis when CMV-CMI is detected and to continue with preemptive therapy.
• Evaluate incidence of neutropenia with this approach

Bio:

Thilagavathi Venkatachalam, Kidney Transplant Fellow Mayo Arizona July 2023- current

AMA Albuquerque NM; Private Practice – March 2020- Feb 2023

Assistant Professor – 2018 – 2020

Assistant Professor – Cooper University Hospital 2016 – 2018

Attending Cooper University Hospital 2010 - 2016

IM Training and Nephrology fellowship Cooper University Hospital, Camden NJ (2004- 2010)

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.